Frailty, Frailty in Older Adults, Frailty/Sarcopenia, Sarcopenia in Elderly
Conditions
Keywords
sarcopenia, Frailty, Hip Fracture, Older population, Gerontological, Femur fracture, Sarcopenia and Frailty
Brief summary
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
Interventions
DRUGIsomyosamine 250mg
Isomyosamine 250 mg capsules dosed 4 times daily
DRUGPlacebo 250 mg
Placebo 250 mg capsule 4 times daily
Sponsors
TNF Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age 60 to 85 years of age 2. Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall 3. Concomitant medication limited to treatment for chronic conditions 4. The ability to give informed consent and comply with study procedures 5. Body weight ≥35 kg 6. Adequate dietary intake 7. Potential subjects' intention to avoid reproductive activity will be confirmed And one or more of the following criteria: 8. Previous history frailty or sarcopenia diagnosis using standardized tests; 9. Positive assessment for frailty or sarcopenia using standardized tests or as per clinician's judgement; 10. Previous positive assessment for elevated biomarkers of inflammation (serum IL-6 level\> LOQ, TNFR1 level \> LOQ, and/or TNF-alpha level \> LOQ)
Exclusion criteria
1. Receiving immunotherapy for cancer or solid organ transplantation 2. Complex or comminuted fracture or fracture of multiple long bones 3. Regular treatment for chronic disease including chronic renal failure, chronic heart failure (CHF) cerebrovascular disease including stroke, rheumatoid arthritis, or polymyalgia rheumatica 4. Chronic kidney disease (estimated glomerular filtration rate \[eGFR\] \<60 mL/min) 5. Newly (\< 2 weeks) diagnosed COVID-19 6. Inability or unwillingness to give written informed consent 7. History of upper/lower respiratory tract infection, requiring systemic steroids, antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit 8. History of adverse reaction or allergy to TNF inhibitor 9. History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion 10. Currently under treatment by an anti-TNFα drug, such as adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and biosimilars 11. Currently under treatment by an anti-diabetic medication, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide, or any of metformin, jenuvia, or insulin 12. Unwillingness or inability to comply with study procedures, including smoking cessation 13. History of epilepsy or seizure propensity, ataxia, abnormal EEG findings, abnormal brain magnetic resonance image, or other co-morbid neurological conditions 14. Positive TB test 15. Patients who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Short Physical Performance Battery (SPPB) Test in subjects treated with Isomyosamine or placebo | From enrollment to the end of treatment at 90 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 4-meter walk test | From enrollment to the end of treatment at 90 days | Change in the time taken to walk 4 meters through 90 days dosing. |
| 6-minute walk test | From enrollment to the end of treatment at 90 days | Change in the distance walked in the 6-minute walk test (m) through 90 days dosing. |
| Grip strength | From enrollment to the end of treatment at 90 days | Change in grip strength score over 90 day dosing. |
| Effect on serum levels of biochemical markers of TNF activation | From enrollment to the end of treatment at 90 days | — |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in the Isomyosamine vs Placebo groups | From enrollment to the end of treatment at 90 days | — |
Contacts
Primary ContactDan Mazzucco
Outcome results
None listed